The medication will be sold under the brand name Journavx for $15.50 per pill, according to Vertex Pharmaceuticals, the company that developed the new drug. The FDA's sign-off on the medication ...

On Thursday, the Food and Drug Administration (FDA) granted approval to Vertex Pharmaceuticals' non-opioid painkiller pill, a new alternative for pain relief that does not carry the risk of addiction.

The opioid crisis has claimed the lives of over half a million Americans since the beginning of the epidemic, a process ...

The availability of suzetrigine may represent a critical step in addressing the nation’s pain management crisis. While ...

Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and ...

Pain is good. Or finding non-opioid ways to manage it is good, if Latigo Biotherapeutics’ $150 million March fundraise is ...

If that is a signal of reduced efficacy in chronic pain it could be a drag on Journavx peak sales potential, as that is a much larger market opportunity than acute pain. Vertex said it intended to ...

Journavx's approval is an "important public health milestone," according to Jacqueline Corrigan-Curay, acting director of the FDA's Center for Drug Evaluation and Research (CDER). "A new non ...

The non-profit Institute for Clinical and Economic Review has issued a lukewarm final evidence report on Vertex Pharmaceuticals' (NASDAQ:VRTX) non-opioid pain medicine Journavx (suzetrigine).

The message is that Journavx is off to a strong start in its acute pain debut, with good momentum across hospital and retail settings and broad shelf availability, reportedly on close to 90% of U ...